🔬 Pharmidex at "From Innovation to Adoption in Gene Therapies"! 🚀
February 27, 2025

We’re excited to announce that Radhakrishnan Venkatasamy, our Principal Research Scientist specializing in autoimmune diseases, will be attending From Innovation to Adoption in Gene Therapies, hosted by One Nucleus on Thursday, 27 February 2025 at Level 39, Canary Wharf, London.


This event brings together experts to explore the latest advancements in gene therapies, and Radhakrishnan is eager to connect with fellow innovators to discuss new opportunities for collaboration. 

Let’s work together to accelerate drug discovery and development!


📍 Event details:

📅 Date: Thursday, 27 February 2025

⏰ Time: 15:00 – 19:30

📍 Location: Level 39, One Canada Square, Canary Wharf, London E14 5AB

🔗 More info: (https://lnkd.in/efEUWfCJ)

💬 Interested in partnering with Pharmidex? Connect with Radhakrishnan at the event or reach out to us!

#GeneTherapy #Pharmidex #DrugDiscovery #BiotechInnovation #Collaboration

Congratulate Ash Alavijeh as Chief Operating Officer

May 7, 2026
We are delighted to announce and congratulate Ash Alavijeh on his appointment as Chief Operating Officer at Pharmidex . Ash has been an integral part of Pharmidex’s journey, bringing strong leadership, strategic vision and a deep commitment to advancing our capabilities in drug discovery and development. In his new role as COO, he will play a key part in driving operational excellence and supporting the continued growth of the company. This appointment reflects both Ash’s contributions to date and our confidence in his leadership as we continue to expand and evolve. Please join us in congratulating Ash on this well-deserved achievement.

World Asthma Day 🌍

May 5, 2026
Asthma affects over 260 million people worldwide and remains a significant unmet medical need. At Pharmidex , we are proud to support the development of next-generation respiratory therapies through: In vivo respiratory disease models Whole Body Plethysmography (WBP) for functional readouts Integrated PK/PD and bioanalysis Our focus is simple: generate high-quality data that enables confident decision-making and accelerates progress for patients. Because behind every dataset is a patient waiting to breathe easier.

Funding Opportunity for Early-Stage Innovators in Scotland

May 1, 2026
Early-stage innovators based in Scotland have access to a significant opportunity to advance their programs toward ProofOfConcept, with an additional £2.85M fund from the Scottish Government aimed at supporting early development and enabling further investment. 🗓️ Deadline: 8th May At Pharmidex , we work alongside our partners to generate robust, translational data that supports confident decision-making across early discovery and preclinical development. Our capabilities include: TargetExpression ModeOfActionStudies TargetEngagement HitIdentification ADME and PK profiling If you are preparing an application and require scientific input or timely quotations, we would be pleased to support your programme. 🔗 https://lnkd.in/eZ6vVjgN
More Posts